West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) – Investment analysts at Zacks Research raised their FY2026 earnings estimates for West Pharmaceutical Services in a research report issued to clients and investors on Thursday, May 14th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $8.50 per share for the year, up from their prior estimate of $7.85. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $8.61 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q2 2027 earnings at $2.48 EPS and Q4 2027 earnings at $2.47 EPS.
A number of other analysts have also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $315.00 price objective on shares of West Pharmaceutical Services in a report on Friday, February 13th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $295.00 price objective on shares of West Pharmaceutical Services in a report on Tuesday, February 10th. Morgan Stanley set a $315.00 price objective on shares of West Pharmaceutical Services in a report on Monday, April 27th. Evercore reaffirmed an “outperform” rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Finally, Barclays increased their price objective on shares of West Pharmaceutical Services from $275.00 to $310.00 and gave the stock an “equal weight” rating in a report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $322.89.
West Pharmaceutical Services Stock Up 0.5%
Shares of NYSE:WST opened at $304.31 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. West Pharmaceutical Services has a 1-year low of $203.74 and a 1-year high of $330.88. The company’s fifty day moving average is $269.91 and its two-hundred day moving average is $265.43. The stock has a market capitalization of $21.50 billion, a price-to-earnings ratio of 40.68, a price-to-earnings-growth ratio of 2.53 and a beta of 1.17.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The company had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm’s revenue was up 21.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS.
West Pharmaceutical Services declared that its Board of Directors has initiated a share buyback plan on Tuesday, February 17th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 5.6% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.
Insider Transactions at West Pharmaceutical Services
In related news, VP Annette F. Favorite sold 2,817 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares in the company, valued at $5,135,905.60. This represents a 14.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Chad Winters sold 896 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This represents a 37.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.60% of the company’s stock.
Hedge Funds Weigh In On West Pharmaceutical Services
A number of institutional investors and hedge funds have recently bought and sold shares of WST. Elyxium Wealth LLC bought a new position in West Pharmaceutical Services in the 4th quarter valued at about $25,000. CYBER HORNET ETFs LLC bought a new position in West Pharmaceutical Services in the 2nd quarter valued at about $25,000. Cornerstone Planning Group LLC grew its position in West Pharmaceutical Services by 90.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 50 shares in the last quarter. Bayban bought a new position in West Pharmaceutical Services in the 4th quarter valued at about $27,000. Finally, Private Trust Co. NA grew its position in West Pharmaceutical Services by 156.4% in the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 61 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Featured Stories
- Five stocks we like better than West Pharmaceutical Services
- Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade?
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}